American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2014, 2(12), 266-268
DOI: 10.12691/ajmcr-2-12-2
Open AccessCase Report

Non-secretory Primary Plasma Cell Leukemia – A Case Report

Amira Humeida1, , Ihsan M. Osman2, Hiba A Awooda3 and Manal M. ElTahir4

1Elneelain University


3Department of Physiology, Faculty of Medicine and Heath Sciences, Alneelain University, Khartoum, Sudan

4Military Hospital

Pub. Date: November 26, 2014

Cite this paper:
Amira Humeida, Ihsan M. Osman, Hiba A Awooda and Manal M. ElTahir. Non-secretory Primary Plasma Cell Leukemia – A Case Report. American Journal of Medical Case Reports. 2014; 2(12):266-268. doi: 10.12691/ajmcr-2-12-2


Plasma cell leukemia (PCL) is a rare disease and the least common variant of multiple myeloma. It accounts for 2-3% of all plasma cell dyscrasias with poor prognosis. We report a 65 year old Sudanese lady presented to oncology clinic with complaint of inability to walk for 2 weeks. Laboratory findings showed anemia, thrombocytopenia and white blood cell count of 49.4x109/L, 62% of which were plasma cells. Bone marrow aspirate showed infiltration by 75% plasma cells some with abnormal forms, Immunophenotyping revealed plasma cell population which were CD38 and CD138 positive, surface, cytoplasmic kappa and lambda were negative. Plasma protein electrophoresis was normal denoting it as non-secretory plasma cell leukemia. Unfortunately the patient passed away before doing further investigations or receiving any treatment.

Non-secretory plasma cell leukemia

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Flavio Albarracin, Rafael Fonseca. Plasma cell leukemia. Blood Reviews 2011; 25: 107-112
[2]  Blade J, Kyle RA Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13 (6): 1259-72.
[3]  Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22: 1044-52.
[4]  International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
[5]  Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93: 1032-7
[6]  Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, Padilla-Gonzalez Y, Garcia-Chavez J, Tripp-Villanueva F, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002; 81 (7): 362-7.
[7]  Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009; 115 (24): 5734-9.
[8]  Dimopoulas MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukemia. Br J Hematol 1994; 88: 754-9.
[9]  Bernasconi C, Castelli G, Pagnucco G, Brusamolino E. Plasma cell leukemia: A report on 15 patients. Eur J Hematol 1989; 43: 76-83.
[10]  C Ferna´ndez de Larrea, RA Kyle, BGM Durie et. al, on behalf of the International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013, 1-12.
[11]  Hayman SR, Fonseca R. Plasma cell leukemia. Current Treatment Options in Oncology 2001; 1: 205-216.
[12]  Prasad A, Abraham G. Acute renal failure, recovery in a patient with light chain myeloma and? Thalassemia trait. Indian J Nephrol 2005; 15: 243-4.
[13]  Abraham R, Clark R, Bryant S, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chemistry 2002; 48: 655-7.
[14]  Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol 1987; 24: 202-8
[15]  Tohru Takahashi, Shin-ichi Kanno, HidetoItoh, Mitsuru Yoshimoto, Masayuki Tsujisaki and Michihiro Fujino. Two Cases of Nonsecretory Multiple Myeloma Presenting as Primary Plasma Cell Leukemia. Intern Med 53: 2121-2125, 2014
[16]  Agarwal AD, Brahmbhatt BS, Parikh BP, Shah MJ. Plasma cell leukemia: A retrospective study of 10 cases. Indian J Cancer 2014; 51: 18-9.
[17]  Raj R S, Najeeb S, Aruna R, Pavithran K, Thomas M. Primary plasma cell leukemia occuring in the young. Indian J Cancer 2003;40:116-7
[18]  Blade J, Samson D, Reece D, et al. Criteria forevaluating disease response and progression inpatients with multiple myeloma treated by highdosetherapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102 (5): 1115-1123.
[19]  Wilson I. Gonsalves, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Yi Lin, Preet P. Singh, Vinay Gupta, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Prashant Kapoor, Arleigh R. McCurdy, and Shaji K. Kumar. Implications of continued response after autologous stem cell transplantation for multiple myelom. Blood. 2013; 122 (10): 1746-1749.